Effects and mechanism of Chinese medicine Jiawei Yupingfeng in a mouse model of allergic rhinitis.
10.1016/j.joim.2021.01.012
- Author:
Hui CHEN
1
;
Wei FENG
2
;
Ye LU
1
;
Yi YANG
1
;
Zhong-Hai XIN
1
;
Man LI
1
;
Li XIN
1
;
Ying-di GONG
1
Author Information
1. Department of Otolaryngology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
2. Department of Otolaryngology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China. Electronic address: wangjingentsci@126.com.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Allergic rhinitis;
Chinese medicine;
Inflammatory cytokines;
Jiawei Yupingfeng;
Mouse
- MeSH:
Animals;
Disease Models, Animal;
Drugs, Chinese Herbal/pharmacology*;
Medicine, Chinese Traditional;
Mice;
Mice, Inbred BALB C;
Rhinitis, Allergic/drug therapy*
- From:
Journal of Integrative Medicine
2021;19(4):354-361
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:Chinese medicine has the potential to modulate allergic rhinitis (AR). There have been studies investigating the treatment efficacy of Yupingfeng San, alone or in combination with other ingredients, in AR, though few have studied the potential mechanisms of these drugs. In the present study, we measured the effects of Jiawei Yupingfeng (JWYPF), a traditional Chinese medicine formula, on mice with ovalbumin-induced AR and explored its underlying mechanism of action.
METHODS:Forty BALB/c mice were randomly divided into normal control, allergy control and two treatment groups of ten mice each. In the normal control group, mice were sensitized and challenged with saline. The mice in the allergy control and treatment groups were sensitized and challenged with ovalbumin and aluminum hydroxide gel. The treatments of JWYPF and Nasonex were administered intranasally in the AR mice for one week. Several signs of allergic inflammation, such as nasal eosinophils and inflammatory cytokines, were measured to determine the underlying mechanisms.
RESULTS:Mice in the JWYPF and Nasonex groups had significantly lower AR symptom scores than those in the allergy control group (the mean differences between JWYPF and the allergy control, and Nasonex and the allergy control were -2.00 ± 0.35 and -2.40 ± 0.32). After treatment with JWYPF and Nasonex, the levels of ovalbumin-specific IgE and histamine were significantly reduced, as were the levels of interlukin-4 and transforming growth factor-β, while interferon-γ levels were increased (all P < 0.0001, vs. allergy control). These two treatments also significantly inhibited eosinophil and mast cell infiltration into the nasal cavity but were not statistically different from one-another.
CONCLUSION:JWYPF has a potential therapeutic effect on AR via adjusting the rebalance of T helper 1 and T helper 2.
